Search results
Results from the WOW.Com Content Network
Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. [1] They act by antagonizing the α 2 -adrenergic receptor and certain serotonin receptors such as 5-HT 2A and 5-HT 2C , [ 1 ] but also 5-HT 3 , [ 1 ] 5-HT 6 , and/or 5-HT 7 in some cases.
This is an accepted version of this page This is the latest accepted revision, reviewed on 26 January 2025. Long-term brain disorders causing impaired memory, thinking and behavior This article is about the cognitive disorder. For other uses, see Dementia (disambiguation). "Senile" and "Demented" redirect here. For other uses, see Senile (disambiguation) and Demented (disambiguation). Medical ...
Overall, the lifetime dementia risk after age 55 was 35% for men and 48% for women. About a million Americans a year are expected to develop dementia by 2060, roughly double today’s toll ...
Paxil – an antidepressant of the SSRI class; Nardil – an antidepressant of the MAOI class used to treat depression; Orap – a typical antipsychotic used to treat tic disorder; Pristiq (desvenlafaxine) – an antidepressant of the SNRI class; Prolixin (fluphenazine) – typical antipsychotic
A care plan tailored for specific circumstances is prepared after a comprehensive assessment has taken place, and is continuously monitored and modified as needed. [3] A comprehensive geriatric care assessment is thorough and can take anywhere from two to five hours in length, this of course is broken down into two or three assessment visits ...
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
For example, venlafaxine works alongside its primary metabolite O-desmethylvenlafaxine to strongly inhibit serotonin and norepinephrine reuptake in the brain. The evidence also suggests that dopamine and norepinephrine behave in a co-transportational manner, due to the inactivation of dopamine by norepinephrine reuptake in the frontal cortex ...
In 2005, the FDA issued an advisory warning of an increased risk of death when atypical antipsychotics are used in dementia. [47] In the subsequent 5 years, the use of atypical antipsychotics to treat dementia decreased by nearly 50%. [47] As of now, the only FDA-approved atypical antipsychotic for alzheimer-related dementia is brexpiprazole.